The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population.

Baseline angiographic lesion characteristics predictive of clinical responsePublished in peer-reviewed journal Ophthalmic Surgery, Lasers and ...

Although AI shows significant promise in diagnosing and managing age-related macular degeneration, its efficacy is reduced by bias, data quality and limited generalizability, according to a review ...

The Macula Society is a forum for new research in retinal vascular and macular diseases. David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial demonstrating that ...

Brolucizumab stabilizes retinal exudation and fluid, improving visual outcomes in wet AMD management ... and to spectral-domain optical coherence tomography (SD-OCT) imaging.

Wet AMD is the leading cause of vision loss in the elderly, affecting around three million people in the US and Europe and driving a retinal disease market that is worth upwards of $18 billion a year.

Wet AMD treatments can be costly ... It may also include coverage for tests like optical coherence tomography (OCT) and fluorescein angiography. Doctors use these tests to monitor disease ...

Optical coherence tomography (OCT): Uses imaging to ... to highlight abnormal blood vessels in the retina (used mainly for wet AMD diagnosis). While there is no cure for AMD, treatments can ...